Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » 10X Genomics

10X Genomics

 

10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.

 

10X Genomics Company Profile  

 

President & CEO: Serge Saxonov

CEO photo:

 10X Genomics CEO photo - Serge Saxonov

Website: http://10xgenomics.com

Headquarters: Pleasanton, CA

10x Genomics employees: 101-250

Funding: $113M USD

Founded: 2012

Founders: Serge Saxonov, Ben Hindson


 

10x Genomics News 

Jan 12, 2021

JP Morgan Healthcare Conference 2021, Day 2: Roche, Seer, 10x, Guardant, Hologic, Thermo Fisher

Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.

Dec 30, 2020

Spatial Biology Interest, Products Mushroomed in 2020

Premium

New cellular and molecular spatial biology methods, companies, and product offerings have made this area one of the hottest in the life science market.

Nov 10, 2020

10x Genomics Q3 Revenues Up 17 Percent

For the three months ended Sept. 30, the company reported $71.8 million in revenues, up from $61.2 million in Q3 2019 and beating the average Wall Street estimate.

Oct 14, 2020

10x Genomics Acquisitions Point Towards New In Situ Analyisis Platform

Premium

10x will develop a third genomics platform, possibly combining Cartana's more sensitive chemistry with ReadCoor's instrument.

Oct 05, 2020

10x Genomics to Acquire ReadCoor for $350M, Cartana for $41.2M

The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.

Sep 18, 2020

New Products Posted to GenomeWeb: Sanford Burnham Prebys, 10x Genomics, Bio-Rad, More

Sep 11, 2020

10x Genomics Prices Upsized $440M Public Offering

The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.

Sep 09, 2020

10x Genomics to Sell 3.5M Shares in Public Offering

The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.

Aug 11, 2020

10x Genomics Q2 Revenues Fall 23 Percent but Beat Wall Street Estimates

The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.

Aug 03, 2020

US Appeals Court Lifts Injunction on 10x Genomics' Linked-Reads, Single-Cell CNV Assays

The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.

Pages

The Scan

Victim Identified with Genetic Genealogy

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

Shift to New Variant Work

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

PNAS Papers on Chemotherapy-Induced Cardiac Injury Target, Viral Insertions, SMRT Methylation Profiling

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.